Gerrit Los

5.5k total citations · 2 hit papers
94 papers, 4.1k citations indexed

About

Gerrit Los is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Gerrit Los has authored 94 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Molecular Biology, 35 papers in Oncology and 20 papers in Pathology and Forensic Medicine. Recurrent topics in Gerrit Los's work include Chemotherapy-induced organ toxicity mitigation (13 papers), DNA Repair Mechanisms (12 papers) and Intraperitoneal and Appendiceal Malignancies (11 papers). Gerrit Los is often cited by papers focused on Chemotherapy-induced organ toxicity mitigation (13 papers), DNA Repair Mechanisms (12 papers) and Intraperitoneal and Appendiceal Malignancies (11 papers). Gerrit Los collaborates with scholars based in United States, Netherlands and United Kingdom. Gerrit Los's co-authors include J. G. McVie, James G. Christensen, Maria E. Arango, P.H.A. Mutsaers, Barbara Mroczkowski, Helen Y. Zou, Joseph H. Lee, Qiuhua Li, Shinji Yamazaki and Scott R. McDonnell and has published in prestigious journals such as Nature Genetics, Journal of Clinical Oncology and Blood.

In The Last Decade

Gerrit Los

93 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms

2007 593 citations Helen Y. Zou, Qiuhua Li et al. Cancer Research profile →
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

2007 513 citations James G. Christensen, Helen Y. Zou et al. Molecular Cancer Therapeutics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gerrit Los United States	33	1.8k	1.7k	1.0k	838	505	94	4.1k
James L. Speyer United States	37	928 0.5×	2.2k 1.3×	788 0.8×	1.0k 1.2×	669 1.3×	94	4.4k
Jing Yi United States	21	1.2k 0.7×	3.2k 1.9×	1.7k 1.7×	519 0.6×	812 1.6×	34	5.1k
E Reed United States	33	2.5k 1.4×	2.0k 1.2×	811 0.8×	544 0.6×	437 0.9×	82	4.7k
Michele Orditura Italy	44	1.9k 1.0×	3.4k 2.0×	2.1k 2.0×	1.2k 1.4×	228 0.5×	181	6.1k
Gaetano Facchini Italy	32	1.1k 0.6×	1.2k 0.7×	1.2k 1.1×	685 0.8×	278 0.6×	189	3.4k
M. E. Scheulen Germany	36	2.3k 1.3×	2.6k 1.6×	1.2k 1.1×	422 0.5×	92 0.2×	178	5.5k
Yuji Takebayashi Japan	35	1.9k 1.1×	1.8k 1.1×	502 0.5×	404 0.5×	175 0.3×	82	3.6k
Junji Matsui Japan	31	2.0k 1.1×	1.8k 1.0×	988 1.0×	730 0.9×	97 0.2×	91	5.7k
Tetsuya Hamaguchi Japan	37	1.4k 0.8×	2.3k 1.4×	1.2k 1.1×	804 1.0×	76 0.2×	217	4.5k
A. Hilary Calvert United Kingdom	37	2.3k 1.2×	3.0k 1.8×	1.1k 1.0×	619 0.7×	411 0.8×	75	5.9k

Countries citing papers authored by Gerrit Los

Since Specialization

Citations

This map shows the geographic impact of Gerrit Los's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerrit Los with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerrit Los more than expected).

Fields of papers citing papers by Gerrit Los

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerrit Los. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerrit Los. The network helps show where Gerrit Los may publish in the future.

Co-authorship network of co-authors of Gerrit Los

This figure shows the co-authorship network connecting the top 25 collaborators of Gerrit Los. A scholar is included among the top collaborators of Gerrit Los based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerrit Los. Gerrit Los is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kong, Tim, Angelo B. A. Laranjeira, Christopher T. Letson, et al.. (2024). RSK1 dependency in FLT3-ITD acute myeloid leukemia. Blood Cancer Journal. 14(1). 207–207. 2 indexed citations

Kuruma, Hidetoshi, Hiroaki Matsumoto, Masaki Shiota, et al.. (2013). A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo. Molecular Cancer Therapeutics. 12(5). 567–576. 86 indexed citations

Zou, Helen Y., Qiuhua Li, Joseph H. Lee, et al.. (2012). Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor. Molecular Cancer Therapeutics. 11(4). 1036–1047. 57 indexed citations

Zhu, Zhou, Wenyue Hu, Heather Estrella, et al.. (2012). Dose-dependent effects of small-molecule antagonists on the genomic landscape of androgen receptor binding. BMC Genomics. 13(1). 355–355. 7 indexed citations

Zhang, Cathy C., Zhengming Yan, Qin Zhang, et al.. (2010). PF-03732010: A Fully Human Monoclonal Antibody against P-Cadherin with Antitumor and Antimetastatic Activity. Clinical Cancer Research. 16(21). 5177–5188. 58 indexed citations

Mukhopadhyay, Asima, Ahmed Elattar, Sarah Wilkinson, et al.. (2010). Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors. Clinical Cancer Research. 16(8). 2344–2351. 207 indexed citations

Zou, Helen Y., Qiuhua Li, Joseph H. Lee, et al.. (2007). An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms. Cancer Research. 67(9). 4408–4417. 593 indexed citations breakdown →

Christensen, James G., Helen Y. Zou, Maria E. Arango, et al.. (2007). Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Molecular Cancer Therapeutics. 6(12). 3314–3322. 513 indexed citations breakdown →

Zhang, Cathy C., Susan E. Kephart, Indrawan McAlpine, et al.. (2005). AG-024322 is a potent and selective multi-targeted CDK inhibitor with broad spectrum anti-proliferative activity. Cancer Research. 65. 1045–1045. 8 indexed citations

10.

Cruz‐Monserrate, Zobeida, Hélène C. Vervoort, Ruoli Bai, et al.. (2003). Diazonamide A and a Synthetic Structural Analog: Disruptive Effects on Mitosis and Cellular Microtubules and Analysis of Their Interactions with Tubulin. Molecular Pharmacology. 63(6). 1273–1280. 95 indexed citations

11.

Lin, Xinjian, Dennis Gately, Doreen K. Hom, et al.. (2001). Quantification of tumor cell injuryin vitro andin vivo using expression of green fluorescent protein under the control of theGADD153 promoter. International Journal of Cancer. 91(4). 555–562. 6 indexed citations

12.

Aebi, Stefan, Thomas W. Schnider, Gerrit Los, et al.. (1999). A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel. Cancer Chemotherapy and Pharmacology. 44(3). 259–265. 16 indexed citations

13.

Jones, Jeffrey A., et al.. (1995). Enhancement of drug sensitivity of human malignancies by epidermal growth factor. British Journal of Cancer. 72(3). 615–619. 27 indexed citations

14.

Gately, DP, et al.. (1994). Induction of the growth arrest and DNA damage-inducible gene GADD153 by cisplatin in vitro and in vivo. British Journal of Cancer. 70(6). 1102–1106. 36 indexed citations

15.

Los, Gerrit, M. van Vugt, & Herbert M. Pinedo. (1994). Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. British Journal of Cancer. 69(2). 235–241. 105 indexed citations

16.

Los, Gerrit, et al.. (1993). Combination treatment of cis- and carboplatin in cancers restricted to the peritoneal cavity in the rat. Cancer Chemotherapy and Pharmacology. 32(6). 425–433. 6 indexed citations

17.

Los, Gerrit, et al.. (1993). Effects of temperature on the interaction of cisplatin and carboplatin with cellular DNA. Biochemical Pharmacology. 46(7). 1229–1237. 40 indexed citations

18.

Underberg, W.J.M., et al.. (1992). Platinum antitumour agents: A review of (bio)analysis. Pharmacy World & Science. 14(3). 61–77. 10 indexed citations

19.

Los, Gerrit, Els M.E. Verdegaal, H.P.J.M. Noteborn, et al.. (1991). Cellular pharmacokinetics of carboplatin and cisplatin in relation to their cytotoxic action. Biochemical Pharmacology. 42(2). 357–363. 40 indexed citations

20.

Los, Gerrit, et al.. (1991). Antitumour response and nephrotoxicity following intraperitoneal administration of a slow release formulation of cisplatin to rats bearing cancers restricted to the peritoneal cavity. British Journal of Cancer. 64(1). 90–92. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact